Related Experiment Video

Updated: Jun 21, 2026

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
09:29

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Published on: March 20, 2020

Pharmacotherapy of triple-negative breast cancer

Cagatay Arslan1, Omer Dizdar, Kadri Altundag

  • 1Hacettepe University Institute of Oncology, Department of Medical Oncology, 06100 Sihhiye, Ankara, Turkey.

Expert Opinion on Pharmacotherapy
|July 31, 2009
PubMed

Insights

Triple-negative breast cancer (TNBC) lacks targeted therapies, leading to aggressive disease and high relapse rates. Research explores TNBC

Area of Science:

  • Oncology
  • Genetics
  • Pathology

Background:

  • Triple-negative breast cancer (TNBC) comprises 15% of breast cancers, characterized by a lack of estrogen receptors, progesterone receptors, and Her2.
  • TNBC tumors are typically poorly differentiated, exhibit aggressive clinical behavior, and share similarities with basal-like breast cancer.
  • Limited treatment options exist for TNBC due to the absence of specific molecular targets and inherent resistance to endocrine therapy and trastuzumab.

Purpose of the Study:

  • To review current and future treatment strategies for triple-negative breast cancer.
  • To discuss new insights into proliferative pathways driving TNBC pathogenesis.
  • To explore potential therapeutic approaches based on TNBC's similarities with BRCA-1-associated breast cancer.

Main Methods:

  • Literature review of studies on triple-negative breast cancer.
  • Analysis of histological and genetic characteristics of TNBC.
  • Examination of biological and clinical data comparing TNBC and basal-like breast cancer.
  • Investigation of proliferative pathways implicated in TNBC development.

Main Results:

  • TNBC exhibits aggressive characteristics and high relapse rates with standard treatments.
  • Significant overlap in biological and clinical features exists between TNBC and basal-like breast cancer.
  • TNBC shares genetic and histological similarities with BRCA-1-associated breast cancer.
  • Current treatment approaches for TNBC are limited, lacking targeted therapies.

Conclusions:

  • Triple-negative breast cancer presents a significant clinical challenge due to its aggressive nature and limited therapeutic options.
  • Understanding the underlying proliferative pathways and genetic similarities, particularly with BRCA-1-associated cancers, is crucial for developing novel treatments.
  • Future research should focus on targeted therapies and chemotherapeutics that address the specific biology of TNBC.

More Related Videos

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...